National Audit of Metastatic Breast Cancer Report 2024 (NAoMe)
The National Audit of Metastatic Breast Cancer (NAoMe), part of the National Cancer Audit Collaborating Centre (NATCAN), has published a State of the Nation 2024 report on the care received by women and men diagnosed with metastatic breast cancer (MBC) during 2019-21 in England and Wales.
It provides baseline information on performance indicators selected to monitor progress against the following five NAoMe quality improvement goals:
- Improve the movement of patients through the care pathway
- Reduce unwarranted variation in access and timeliness to systemic anti-cancer treatment
- Reduce unwarranted variation in access and timeliness to palliative treatments
- Improve access to nursing support
- Improve and reduce variation in MBC outcomes.
The report also contains four recommendations:
- Ensure the care for people newly diagnosed with MBC (either de-novo or recurrent) is discussed within a breast multidisciplinary team (MDT) meeting
- Examine biopsy rates for MBC and aim to increase this where feasible if the results may have therapeutic implications
- Confirm breast MDTs have a data lead responsible for ensuring the quality of national data submissions
- Ensure the recording of date and type of breast cancer recurrence in cancer datasets.
Read the full report: You can view the report by clicking the button below.
Stay up-to-date: For notifications of future reports from HQIP, sign up to our mailing list.
This report was originally published on 12th September 2024. Version 2: October 2024 – This version of the report amends 13 numbers incorrectly reported on pages 12, 13, and 14 for key messages 5.2, 5.3, 5.4, 5.5, and 5.6.
